JP7381500B2 - 外傷性脳損傷を検出するための組成物および方法 - Google Patents

外傷性脳損傷を検出するための組成物および方法 Download PDF

Info

Publication number: JP7381500B2
Authority: JP; Japan
Prior art keywords: carbons; alkyl; heteroarylene; heterocycloalkyl; cycloalkyl
Prior art date: 2018-05-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2020567093A

Other languages

English (en)

Japanese (ja)

Other versions

JP2021525875A (ja

JP2021525875A5 (fr

Inventor

ステラサッラーフ，

リンジーエム．ランドルフ，

スハイルラスール，

Original Assignee

アミディス，インコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-05-31

Filing date

2019-05-31

Publication date

2023-11-15

2019-05-31 Application filed by アミディス，インコーポレイテッド filed Critical アミディス，インコーポレイテッド

2021-09-27 Publication of JP2021525875A publication Critical patent/JP2021525875A/ja

2022-05-17 Publication of JP2021525875A5 publication Critical patent/JP2021525875A5/ja

2023-11-02 Priority to JP2023188467A priority Critical patent/JP7583895B2/ja

2023-11-15 Application granted granted Critical

2023-11-15 Publication of JP7381500B2 publication Critical patent/JP7381500B2/ja

2024-11-01 Priority to JP2024192794A priority patent/JP2025016675A/ja

Status Active legal-status Critical Current

2039-05-31 Anticipated expiration legal-status Critical

Links

208000030886 Traumatic Brain injury Diseases 0.000 title claims description 100
230000009529 traumatic brain injury Effects 0.000 title claims description 100
238000000034 method Methods 0.000 title claims description 76
239000000203 mixture Substances 0.000 title claims description 53
150000001875 compounds Chemical class 0.000 claims description 196
125000000217 alkyl group Chemical group 0.000 claims description 190
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 155
125000005549 heteroarylene group Chemical group 0.000 claims description 152
125000000753 cycloalkyl group Chemical group 0.000 claims description 135
125000004404 heteroalkyl group Chemical group 0.000 claims description 132
125000000732 arylene group Chemical group 0.000 claims description 128
229910052739 hydrogen Inorganic materials 0.000 claims description 103
239000001257 hydrogen Substances 0.000 claims description 98
239000000523 sample Substances 0.000 claims description 77
102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 55
108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 55
230000002207 retinal effect Effects 0.000 claims description 54
229910052736 halogen Inorganic materials 0.000 claims description 46
150000002367 halogens Chemical class 0.000 claims description 46
210000001525 retina Anatomy 0.000 claims description 38
238000001514 detection method Methods 0.000 claims description 37
238000003384 imaging method Methods 0.000 claims description 33
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 30
208000024827 Alzheimer disease Diseases 0.000 claims description 21
125000000304 alkynyl group Chemical group 0.000 claims description 19
239000002202 Polyethylene glycol Substances 0.000 claims description 18
229920001223 polyethylene glycol Polymers 0.000 claims description 18
229920001451 polypropylene glycol Polymers 0.000 claims description 18
125000003342 alkenyl group Chemical group 0.000 claims description 17
125000004432 carbon atom Chemical group C* 0.000 claims description 17
229910052760 oxygen Inorganic materials 0.000 claims description 17
210000003128 head Anatomy 0.000 claims description 14
229910052717 sulfur Inorganic materials 0.000 claims description 14
125000003545 alkoxy group Chemical group 0.000 claims description 13
230000035939 shock Effects 0.000 claims description 13
238000001727 in vivo Methods 0.000 claims description 12
125000004076 pyridyl group Chemical group 0.000 claims description 11
238000003745 diagnosis Methods 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 9
229920001577 copolymer Polymers 0.000 claims description 9
238000001990 intravenous administration Methods 0.000 claims description 7
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 6
230000003287 optical effect Effects 0.000 claims description 6
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
229910006069 SO3H Inorganic materials 0.000 claims description 4
230000037081 physical activity Effects 0.000 claims description 4
150000002431 hydrogen Chemical class 0.000 claims 18
125000004435 hydrogen atom Chemical class [H]* 0.000 description 58
-1 (cyclohexyl)methyl Chemical group 0.000 description 45
241000699670 Mus sp. Species 0.000 description 44
210000001508 eye Anatomy 0.000 description 30
150000003839 salts Chemical class 0.000 description 29
229940125904 compound 1 Drugs 0.000 description 28
239000006196 drop Substances 0.000 description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
125000003118 aryl group Chemical group 0.000 description 23
201000010099 disease Diseases 0.000 description 23
230000006378 damage Effects 0.000 description 21
208000027418 Wounds and injury Diseases 0.000 description 20
208000014674 injury Diseases 0.000 description 20
210000001519 tissue Anatomy 0.000 description 20
125000001072 heteroaryl group Chemical group 0.000 description 18
210000004556 brain Anatomy 0.000 description 17
208000024891 symptom Diseases 0.000 description 17
125000001424 substituent group Chemical group 0.000 description 16
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 15
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 14
239000008194 pharmaceutical composition Substances 0.000 description 14
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 13
125000004429 atom Chemical group 0.000 description 13
238000010172 mouse model Methods 0.000 description 13
238000009472 formulation Methods 0.000 description 12
238000013456 study Methods 0.000 description 12
238000003786 synthesis reaction Methods 0.000 description 12
QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 11
239000002253 acid Substances 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
239000000243 solution Substances 0.000 description 11
238000011282 treatment Methods 0.000 description 11
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 10
KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 10
229940125833 compound 23 Drugs 0.000 description 10
125000004093 cyano group Chemical group *C#N 0.000 description 10
238000010186 staining Methods 0.000 description 10
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 9
229910052805 deuterium Inorganic materials 0.000 description 9
239000003814 drug Substances 0.000 description 9
238000002189 fluorescence spectrum Methods 0.000 description 9
239000012453 solvate Substances 0.000 description 9
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
238000009825 accumulation Methods 0.000 description 8
238000007428 craniotomy Methods 0.000 description 8
229940079593 drug Drugs 0.000 description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
125000005842 heteroatom Chemical group 0.000 description 8
229910052757 nitrogen Inorganic materials 0.000 description 8
MAARRMBCEFVKNV-UHFFFAOYSA-N (6-bromonaphthalen-2-yl)methanol Chemical compound C1=C(Br)C=CC2=CC(CO)=CC=C21 MAARRMBCEFVKNV-UHFFFAOYSA-N 0.000 description 7
150000001412 amines Chemical class 0.000 description 7
239000004615 ingredient Substances 0.000 description 7
125000003107 substituted aryl group Chemical group 0.000 description 7
238000012360 testing method Methods 0.000 description 7
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
208000029028 brain injury Diseases 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
230000001054 cortical effect Effects 0.000 description 6
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
125000005843 halogen group Chemical group 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
150000003254 radicals Chemical class 0.000 description 6
VUVIRKAVBZITDO-UHFFFAOYSA-N 1-bromonaphthalene-2-carboxylic acid Chemical compound C1=CC=CC2=C(Br)C(C(=O)O)=CC=C21 VUVIRKAVBZITDO-UHFFFAOYSA-N 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
206010002091 Anaesthesia Diseases 0.000 description 5
125000006725 C1-C10 alkenyl group Chemical group 0.000 description 5
241000282412 Homo Species 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
208000018737 Parkinson disease Diseases 0.000 description 5
230000006933 amyloid-beta aggregation Effects 0.000 description 5
230000037005 anaesthesia Effects 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
210000005013 brain tissue Anatomy 0.000 description 5
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
230000000694 effects Effects 0.000 description 5
235000019439 ethyl acetate Nutrition 0.000 description 5
239000007850 fluorescent dye Substances 0.000 description 5
125000000623 heterocyclic group Chemical group 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
210000003625 skull Anatomy 0.000 description 5
238000003756 stirring Methods 0.000 description 5
125000000547 substituted alkyl group Chemical group 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 4
NQQRXZOPZBKCNF-NSCUHMNNSA-N (e)-but-2-enamide Chemical compound C\C=C\C(N)=O NQQRXZOPZBKCNF-NSCUHMNNSA-N 0.000 description 4
DLLDUYJRQNTEOR-UHFFFAOYSA-N 6-bromonaphthalene-2-carbaldehyde Chemical compound C1=C(C=O)C=CC2=CC(Br)=CC=C21 DLLDUYJRQNTEOR-UHFFFAOYSA-N 0.000 description 4
ZLCRNYUTFHRRJQ-UHFFFAOYSA-N 6-piperidin-1-ylnaphthalene-2-carbaldehyde Chemical compound C1=CC2=CC(C=O)=CC=C2C=C1N1CCCCC1 ZLCRNYUTFHRRJQ-UHFFFAOYSA-N 0.000 description 4
230000007082 Aβ accumulation Effects 0.000 description 4
206010010904 Convulsion Diseases 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
239000012062 aqueous buffer Substances 0.000 description 4
229940126086 compound 21 Drugs 0.000 description 4
229940126208 compound 22 Drugs 0.000 description 4
239000013058 crude material Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
125000006575 electron-withdrawing group Chemical group 0.000 description 4
JOXWSDNHLSQKCC-UHFFFAOYSA-N ethenesulfonamide Chemical compound NS(=O)(=O)C=C JOXWSDNHLSQKCC-UHFFFAOYSA-N 0.000 description 4
210000005153 frontal cortex Anatomy 0.000 description 4
125000001188 haloalkyl group Chemical group 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
230000035515 penetration Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
230000009257 reactivity Effects 0.000 description 4
125000005017 substituted alkenyl group Chemical group 0.000 description 4
229940124530 sulfonamide Drugs 0.000 description 4
239000000725 suspension Substances 0.000 description 4
150000003852 triazoles Chemical class 0.000 description 4
BBXKSBMSLRRTLU-UHFFFAOYSA-N 2-cyano-N-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]acetamide Chemical compound OCCOCCOCCNC(=O)CC#N BBXKSBMSLRRTLU-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010010071 Coma Diseases 0.000 description 3
206010010254 Concussion Diseases 0.000 description 3
208000000202 Diffuse Axonal Injury Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
208000028979 Skull fracture Diseases 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
229910052786 argon Inorganic materials 0.000 description 3
125000003710 aryl alkyl group Chemical group 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
150000001721 carbon Chemical group 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000009514 concussion Effects 0.000 description 3
230000009521 diffuse axonal injury Effects 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
235000019000 fluorine Nutrition 0.000 description 3
239000012458 free base Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
150000003949 imides Chemical class 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
210000000337 motor cortex Anatomy 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
235000005985 organic acids Nutrition 0.000 description 3
230000007170 pathology Effects 0.000 description 3
229910052698 phosphorus Inorganic materials 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000004233 retinal vasculature Effects 0.000 description 3
229910052710 silicon Inorganic materials 0.000 description 3
KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
208000037259 Amyloid Plaque Diseases 0.000 description 2
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
208000020925 Bipolar disease Diseases 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
241000283707 Capra Species 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
241001269524 Dura Species 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
206010018852 Haematoma Diseases 0.000 description 2
206010019196 Head injury Diseases 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
208000032437 Retinal deposits Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
210000003050 axon Anatomy 0.000 description 2
239000002585 base Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000006931 brain damage Effects 0.000 description 2
231100000874 brain damage Toxicity 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000000969 carrier Substances 0.000 description 2
125000003636 chemical group Chemical group 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
229940125877 compound 31 Drugs 0.000 description 2
238000002591 computed tomography Methods 0.000 description 2
VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
208000017004 dementia pugilistica Diseases 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000002934 diuretic Substances 0.000 description 2
230000036267 drug metabolism Effects 0.000 description 2
125000005610 enamide group Chemical group 0.000 description 2
210000002744 extracellular matrix Anatomy 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
230000000155 isotopic effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
238000002483 medication Methods 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
125000004957 naphthylene group Chemical group 0.000 description 2
230000008693 nausea Effects 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
239000002674 ointment Substances 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
239000003961 penetration enhancing agent Substances 0.000 description 2
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000002600 positron emission tomography Methods 0.000 description 2
208000028173 post-traumatic stress disease Diseases 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
125000003373 pyrazinyl group Chemical group 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
230000011514 reflex Effects 0.000 description 2
230000004256 retinal image Effects 0.000 description 2
210000001210 retinal vessel Anatomy 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
238000002603 single-photon emission computed tomography Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
150000003527 tetrahydropyrans Chemical class 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
OWUGEYYFKKKOKU-HAVVHWLPSA-N (E)-2-cyano-N-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]-3-(6-piperidin-1-ylnaphthalen-2-yl)prop-2-enamide Chemical compound OCCOCCOCCNC(=O)C(=C\c1ccc2cc(ccc2c1)N1CCCCC1)\C#N OWUGEYYFKKKOKU-HAVVHWLPSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
KBBXMRWJFDKQCA-MTJSOVHGSA-N (Z)-2-cyano-3-(6-piperidin-1-ylnaphthalen-2-yl)-N-[[1-[(3,4,5-trihydroxy-6-methoxyoxan-2-yl)methyl]triazol-4-yl]methyl]prop-2-enamide Chemical compound C(#N)/C(/C(=O)NCC=1N=NN(C=1)CC1OC(C(C(C1O)O)O)OC)=C/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1 KBBXMRWJFDKQCA-MTJSOVHGSA-N 0.000 description 1
KBBXMRWJFDKQCA-DSGJJCQYSA-N (Z)-2-cyano-3-(6-piperidin-1-ylnaphthalen-2-yl)-N-[[1-[[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl]triazol-4-yl]methyl]prop-2-enamide Chemical compound C(#N)/C(/C(=O)NCC=1N=NN(C1)C[C@H]1O[C@@H]([C@@H]([C@H]([C@@H]1O)O)O)OC)=C/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1 KBBXMRWJFDKQCA-DSGJJCQYSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
230000035502 ADME Effects 0.000 description 1
239000012109 Alexa Fluor 568 Substances 0.000 description 1
206010001854 Altered state of consciousness Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
208000007204 Brain death Diseases 0.000 description 1
HMLLNSLFFNYGRX-WQRHYEAKSA-N C(#N)/C(/C(=O)NC1C(OC(C(C1O)O)CO)O)=C/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1 Chemical compound C(#N)/C(/C(=O)NC1C(OC(C(C1O)O)CO)O)=C/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1 HMLLNSLFFNYGRX-WQRHYEAKSA-N 0.000 description 1
HMLLNSLFFNYGRX-UHFFFAOYSA-N C(#N)/C(/C(=O)NC1C(OC(C(C1O)O)CO)O)=CC1=CC2=CC=C(C=C2C=C1)N1CCCCC1 Chemical compound C(#N)/C(/C(=O)NC1C(OC(C(C1O)O)CO)O)=CC1=CC2=CC=C(C=C2C=C1)N1CCCCC1 HMLLNSLFFNYGRX-UHFFFAOYSA-N 0.000 description 1
UXWLVLJBMMGOGL-ODLFYWEKSA-N C(#N)/C(/C(=O)NCC(CO)O)=C/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1 Chemical compound C(#N)/C(/C(=O)NCC(CO)O)=C/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1 UXWLVLJBMMGOGL-ODLFYWEKSA-N 0.000 description 1
UXWLVLJBMMGOGL-UHFFFAOYSA-N C(#N)/C(/C(=O)NCC(CO)O)=CC1=CC2=CC=C(C=C2C=C1)N1CCCCC1 Chemical compound C(#N)/C(/C(=O)NCC(CO)O)=CC1=CC2=CC=C(C=C2C=C1)N1CCCCC1 UXWLVLJBMMGOGL-UHFFFAOYSA-N 0.000 description 1
MUCQBPLXHABTJC-XARSURHKSA-N C(#N)/C(/C(=O)NC[C@H]1OC(C(C(C1O)O)O)O)=C/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1 Chemical compound C(#N)/C(/C(=O)NC[C@H]1OC(C(C(C1O)O)O)O)=C/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1 MUCQBPLXHABTJC-XARSURHKSA-N 0.000 description 1
MUCQBPLXHABTJC-AXYUOHRYSA-N C(#N)/C(/C(=O)NC[C@H]1OC(C(C(C1O)O)O)O)=CC1=CC2=CC=C(C=C2C=C1)N1CCCCC1 Chemical compound C(#N)/C(/C(=O)NC[C@H]1OC(C(C(C1O)O)O)O)=CC1=CC2=CC=C(C=C2C=C1)N1CCCCC1 MUCQBPLXHABTJC-AXYUOHRYSA-N 0.000 description 1
MUCQBPLXHABTJC-GGLZGAJASA-N C(#N)/C(/C(=O)NC[C@H]1OC([C@@H]([C@H]([C@@H]1O)O)O)O)=C/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1 Chemical compound C(#N)/C(/C(=O)NC[C@H]1OC([C@@H]([C@H]([C@@H]1O)O)O)O)=C/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1 MUCQBPLXHABTJC-GGLZGAJASA-N 0.000 description 1
MUCQBPLXHABTJC-JVGOVNBASA-N C(#N)/C(/C(=O)NC[C@H]1OC([C@@H]([C@H]([C@@H]1O)O)O)O)=CC1=CC2=CC=C(C=C2C=C1)N1CCCCC1 Chemical compound C(#N)/C(/C(=O)NC[C@H]1OC([C@@H]([C@H]([C@@H]1O)O)O)O)=CC1=CC2=CC=C(C=C2C=C1)N1CCCCC1 MUCQBPLXHABTJC-JVGOVNBASA-N 0.000 description 1
HMLLNSLFFNYGRX-ZCDRVEMVSA-N C(#N)/C(/C(=O)N[C@H]1C(O[C@@H]([C@H]([C@@H]1O)O)CO)O)=C/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1 Chemical compound C(#N)/C(/C(=O)N[C@H]1C(O[C@@H]([C@H]([C@@H]1O)O)CO)O)=C/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1 HMLLNSLFFNYGRX-ZCDRVEMVSA-N 0.000 description 1
HMLLNSLFFNYGRX-OQPYTZTLSA-N C(#N)/C(/C(=O)N[C@H]1C(O[C@@H]([C@H]([C@@H]1O)O)CO)O)=CC1=CC2=CC=C(C=C2C=C1)N1CCCCC1 Chemical compound C(#N)/C(/C(=O)N[C@H]1C(O[C@@H]([C@H]([C@@H]1O)O)CO)O)=CC1=CC2=CC=C(C=C2C=C1)N1CCCCC1 HMLLNSLFFNYGRX-OQPYTZTLSA-N 0.000 description 1
ACYGJNAHZYKGOT-CJLVFECKSA-N C(#N)/C(=C(/C)C1=CC2=CC=C(C=C2C=C1)N1CCCCC1)/S(=O)(=O)NCC(CO)O Chemical compound C(#N)/C(=C(/C)C1=CC2=CC=C(C=C2C=C1)N1CCCCC1)/S(=O)(=O)NCC(CO)O ACYGJNAHZYKGOT-CJLVFECKSA-N 0.000 description 1
ACYGJNAHZYKGOT-JWGURIENSA-N C(#N)/C(=C(C)/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1)/S(=O)(=O)NCC(CO)O Chemical compound C(#N)/C(=C(C)/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1)/S(=O)(=O)NCC(CO)O ACYGJNAHZYKGOT-JWGURIENSA-N 0.000 description 1
AEKHKXRZUFTQSY-NHDPSOOVSA-N C(#N)/C(=C/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1)/S(=O)(=O)NCC(CO)O Chemical compound C(#N)/C(=C/C1=CC2=CC=C(C=C2C=C1)N1CCCCC1)/S(=O)(=O)NCC(CO)O AEKHKXRZUFTQSY-NHDPSOOVSA-N 0.000 description 1
AEKHKXRZUFTQSY-UHFFFAOYSA-N C(#N)/C(=CC1=CC2=CC=C(C=C2C=C1)N1CCCCC1)/S(=O)(=O)NCC(CO)O Chemical compound C(#N)/C(=CC1=CC2=CC=C(C=C2C=C1)N1CCCCC1)/S(=O)(=O)NCC(CO)O AEKHKXRZUFTQSY-UHFFFAOYSA-N 0.000 description 1
KBBXMRWJFDKQCA-CIAFOILYSA-N COC1OC(CN2C=C(CNC(=O)C(=C\C3=CC4=CC=C(C=C4C=C3)N3CCCCC3)\C#N)N=N2)C(O)C(O)C1O Chemical compound COC1OC(CN2C=C(CNC(=O)C(=C\C3=CC4=CC=C(C=C4C=C3)N3CCCCC3)\C#N)N=N2)C(O)C(O)C1O KBBXMRWJFDKQCA-CIAFOILYSA-N 0.000 description 1
KBBXMRWJFDKQCA-NOACQDQKSA-N CO[C@H]1O[C@H](CN2C=C(CNC(=O)C(=C\C3=CC4=CC=C(C=C4C=C3)N3CCCCC3)\C#N)N=N2)[C@@H](O)[C@H](O)[C@H]1O Chemical compound CO[C@H]1O[C@H](CN2C=C(CNC(=O)C(=C\C3=CC4=CC=C(C=C4C=C3)N3CCCCC3)\C#N)N=N2)[C@@H](O)[C@H](O)[C@H]1O KBBXMRWJFDKQCA-NOACQDQKSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010013887 Dysarthria Diseases 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
208000006550 Mydriasis Diseases 0.000 description 1
UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
WDUAOPYBCSNQKX-UHFFFAOYSA-N N1(CCCCC1)C=1C=C2C=CC(=CC2=CC1)C1=CC=NC=C1C#N Chemical compound N1(CCCCC1)C=1C=C2C=CC(=CC2=CC1)C1=CC=NC=C1C#N WDUAOPYBCSNQKX-UHFFFAOYSA-N 0.000 description 1
206010028836 Neck pain Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
206010039203 Road traffic accident Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
241001061127 Thione Species 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
125000005466 alkylenyl group Chemical group 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
125000005165 aryl thioxy group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
208000025307 bipolar depression Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
230000008045 co-localization Effects 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
210000000795 conjunctiva Anatomy 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000012043 crude product Substances 0.000 description 1
229940109262 curcumin Drugs 0.000 description 1
235000012754 curcumin Nutrition 0.000 description 1
239000004148 curcumin Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
NSBNXCZCLRBQTA-UHFFFAOYSA-N dibenzyl bis(phenylmethoxy)phosphoryl phosphate Chemical compound C=1C=CC=CC=1COP(OP(=O)(OCC=1C=CC=CC=1)OCC=1C=CC=CC=1)(=O)OCC1=CC=CC=C1 NSBNXCZCLRBQTA-UHFFFAOYSA-N 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
238000002297 emergency surgery Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000004880 explosion Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000002073 fluorescence micrograph Methods 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
125000004438 haloalkoxy group Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
125000002951 idosyl group Chemical class C1([C@@H](O)[C@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000012606 in vitro cell culture Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000030214 innervation Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
230000005445 isotope effect Effects 0.000 description 1
210000004561 lacrimal apparatus Anatomy 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
210000004175 meibomian gland Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
230000004630 mental health Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
229940016409 methylsulfonylmethane Drugs 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
125000006682 monohaloalkyl group Chemical group 0.000 description 1
125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
239000012120 mounting media Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
238000002610 neuroimaging Methods 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
231100000862 numbness Toxicity 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003921 oil Substances 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000036407 pain Effects 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
238000002823 phage display Methods 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
125000006684 polyhaloalkyl group Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
238000011886 postmortem examination Methods 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
210000000162 simple eye Anatomy 0.000 description 1
208000026473 slurred speech Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000008279 sol Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
210000003478 temporal lobe Anatomy 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
238000003354 tissue distribution assay Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
125000005259 triarylamine group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
230000002618 waking effect Effects 0.000 description 1
238000010792 warming Methods 0.000 description 1
239000012224 working solution Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
- A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
- A61B5/4064—Evaluating the brain
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Biophysics (AREA)
Heart & Thoracic Surgery (AREA)
Medical Informatics (AREA)
Surgery (AREA)
Pathology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Psychology (AREA)
Physiology (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Optics & Photonics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Eye Examination Apparatus (AREA)

JP2020567093A 2018-05-31 2019-05-31 外傷性脳損傷を検出するための組成物および方法 Active JP7381500B2 (ja)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
JP2023188467A JP7583895B2 (ja)	2018-05-31	2023-11-02	外傷性脳損傷を検出するための組成物および方法
JP2024192794A JP2025016675A (ja)	2018-05-31	2024-11-01	外傷性脳損傷を検出するための組成物および方法

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201862678900P	2018-05-31	2018-05-31
US62/678,900		2018-05-31
US201862733025P	2018-09-18	2018-09-18
US62/733,025		2018-09-18
PCT/US2019/034977 WO2019232422A1 (fr)	2018-05-31	2019-05-31	Compositions et procédés de détection d'une lésion cérébrale traumatique

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2023188467A Division JP7583895B2 (ja)	2018-05-31	2023-11-02	外傷性脳損傷を検出するための組成物および方法

Publications (3)

Publication Number	Publication Date
JP2021525875A JP2021525875A (ja)	2021-09-27
JP2021525875A5 JP2021525875A5 (fr)	2022-05-17
JP7381500B2 true JP7381500B2 (ja)	2023-11-15

Family

ID=68697319

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2020567093A Active JP7381500B2 (ja)	2018-05-31	2019-05-31	外傷性脳損傷を検出するための組成物および方法
JP2023188467A Active JP7583895B2 (ja)	2018-05-31	2023-11-02	外傷性脳損傷を検出するための組成物および方法
JP2024192794A Pending JP2025016675A (ja)	2018-05-31	2024-11-01	外傷性脳損傷を検出するための組成物および方法

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
JP2023188467A Active JP7583895B2 (ja)	2018-05-31	2023-11-02	外傷性脳損傷を検出するための組成物および方法
JP2024192794A Pending JP2025016675A (ja)	2018-05-31	2024-11-01	外傷性脳損傷を検出するための組成物および方法

Country Status (8)

Country	Link
US (1)	US12478693B2 (fr)
EP (1)	EP3803416A4 (fr)
JP (3)	JP7381500B2 (fr)
CN (2)	CN112424606B9 (fr)
AU (1)	AU2019279001B2 (fr)
CA (1)	CA3100700A1 (fr)
MA (1)	MA52796A (fr)
WO (1)	WO2019232422A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2019372432B2 (en) *	2018-11-02	2025-05-29	Amydis, Inc.	Phosphate compounds for detecting neurological disorders
AU2020348382A1 (en) *	2019-09-18	2022-04-28	Amydis, Inc.	Methods of detecting neurological disorders via binding to phosphorylated tau protein
JP2024525693A (ja) *	2021-07-15	2024-07-12	アミディス，インコーポレイテッド	神経変性障害の診断のためにアミロイドおよびアミロイド様タンパク質を検出するためのフルオロフォアとしてのｎ－ヘテロシクリル置換２－シアノ－３－（ナフタレン－２－イル）アクリルアミド誘導体
WO2024155678A1 (fr) *	2023-01-18	2024-07-25	Amydis, Inc.	Agents de ciblage d'amyloïde

Citations (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020036750A1 (en)	2000-09-23	2002-03-28	Eberl Heinrich A.	System and method for recording the retinal reflex image
JP2012503012A (ja)	2008-09-18	2012-02-02	セダーズ−シナイメディカルセンター	アルツハイマー病を検出するための光学的方法
US20120282169A1 (en)	2009-11-06	2012-11-08	Adlyfe, Inc.	Detection and treatment of traumatic brain injury
JP2013513619A (ja)	2009-12-10	2013-04-22	ザリージェンツオブザユニバーシティオブカリフォルニア	アミロイド結合剤
JP2013545516A (ja)	2010-10-25	2013-12-26	バードナー，スティーブン	アルツハイマー病、外傷性脳損傷、黄斑変性症、複数の神経変性障害および眼疾患の診断、進行および病気経過予想における網膜内のアミロイドの検出装置および方法
WO2015188142A1 (fr)	2014-06-05	2015-12-10	Cedars-Sinai Medical Center	Diagnostic et surveillance d'une lésion cérébrale traumatique par imagerie des anomalies rétiniennes
WO2017004560A1 (fr)	2015-07-02	2017-01-05	The Regents Of The University Of California	Procédés et compositions pour des agrégats amyloïdes
JP2017512834A (ja)	2014-03-19	2017-05-25	アミディス・ダイアグノスティックス・インコーポレイテッド	アミロイド標的剤及びその使用方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5043013A (en)	1987-12-30	1991-08-27	Milliken Research Corporation	Washable ink compositions
US5177064A (en)	1990-07-13	1993-01-05	University Of Florida	Targeted drug delivery via phosphonate derivatives
US6541454B1 (en)	1995-04-04	2003-04-01	Yissum Research Development Company Of The Hebrew University Jerusalem	Phosphonates, biphosphonates and pharmaceutical compositions containing them
US6048662A (en)	1998-12-15	2000-04-11	Bruhnke; John D.	Antireflective coatings comprising poly(oxyalkylene) colorants
JPWO2003020690A1 (ja)	2001-08-29	2004-12-16	協和醗酵工業株式会社	アリールスルファマート誘導体
JP2007504283A (ja)	2003-05-20	2007-03-01	ザリージェンツオブザユニバーシティオブカリフォルニア	β−アミロイド斑に作用物質を結合させる方法
CN101103018A (zh) *	2004-11-16	2008-01-09	神经化学（国际）有限公司	治疗cns和淀粉样蛋白-相关疾病的化合物
ATE525664T1 (de)	2004-11-22	2011-10-15	Abbott Medical Optics Inc	Copolymerisierbare methin- und anthrachinon- verbindungen und artikel damit
JP2009184924A (ja)	2006-05-31	2009-08-20	Eisai R & D Management Co Ltd	生物学的試薬用化合物
JP2008013446A (ja)	2006-07-03	2008-01-24	Neugen Pharma:Kk	酸化ストレスによる細胞変性を分子背景とする難治性疾患の治療または予防剤
EP2046322A4 (fr)	2006-08-02	2010-10-06	Univ Temple	Aryl vinyl sulfures, sulfones, sulfoxides et sulfonamides, dérivés de ceux-ci et utilisations thérapeutiques de ceux-ci
WO2009086303A2 (fr)	2007-12-21	2009-07-09	University Of Rochester	Procédé permettant de modifier la durée de vie d'organismes eucaryotes
EP3231804B1 (fr)	2008-03-21	2021-03-03	The General Hospital Corporation	Composés et compositions pour la détection et le traitement de la maladie d'alzheimer et des troubles apparentés
CN102115429B (zh)	2010-01-06	2013-02-27	中国科学院上海药物研究所	(e)-1-(3,5-二甲氧基苯基)-2-(3,5-二羟基-4-甲氧基苯基)乙烯及其制备方法和用途
KR101194337B1 (ko)	2010-07-14	2012-10-24	웅진코웨이주식회사	레티노이드 유도체 및 그를 포함하는 화장료 조성물
CA2807683C (fr)	2010-08-16	2020-02-18	Cognoptix, Inc.	Systeme et procede pour la detection de proteines amyloides
RU2627694C2 (ru)	2010-10-29	2017-08-10	Клино Лтд.	Производные хинолина, визуализирующий белок тау
US9588129B2 (en)	2013-03-15	2017-03-07	Amira Medical Technologies Inc.	Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
EP3068388A4 (fr)	2013-11-11	2017-04-12	Board of Regents of the University of Texas System	Composés neuroprotecteurs et leur utilisation
EP3068283A1 (fr)	2013-11-12	2016-09-21	Cognoptix, Inc.	Procédé de mesure de fluorescence dans le tissu oculaire
US9605315B2 (en) *	2014-03-26	2017-03-28	The University Of Montana	Detection of traumatic brain injury
WO2016040891A2 (fr)	2014-09-12	2016-03-17	Amydis Diagnostics	Compositions in vitro comprenant un échantillon humain et un agent ciblant les substances amyloïdes
WO2016055148A2 (fr)	2014-10-06	2016-04-14	Université De Genève	Marqueurs et leur utilisation en lien avec une lésion cérébrale
GB201603967D0 (en)	2016-03-08	2016-04-20	Univ Birmingham	Biomarkers of traumatic brain injury
JP7029718B2 (ja)	2017-07-31	2022-03-04	国立研究開発法人量子科学技術研究開発機構	リン酸化タウタンパク質の測定方法
AU2019372432B2 (en) *	2018-11-02	2025-05-29	Amydis, Inc.	Phosphate compounds for detecting neurological disorders
AU2020348382A1 (en)	2019-09-18	2022-04-28	Amydis, Inc.	Methods of detecting neurological disorders via binding to phosphorylated tau protein
IL305647A (en)	2021-03-12	2023-11-01	Amydis Inc	Methods for the detection of systemic amyloidosis by binding to misfolded protein or aggregates
JP2024525693A (ja)	2021-07-15	2024-07-12	アミディス，インコーポレイテッド	神経変性障害の診断のためにアミロイドおよびアミロイド様タンパク質を検出するためのフルオロフォアとしてのｎ－ヘテロシクリル置換２－シアノ－３－（ナフタレン－２－イル）アクリルアミド誘導体
WO2024155678A1 (fr)	2023-01-18	2024-07-25	Amydis, Inc.	Agents de ciblage d'amyloïde

2019
- 2019-05-31 MA MA052796A patent/MA52796A/fr unknown
- 2019-05-31 WO PCT/US2019/034977 patent/WO2019232422A1/fr not_active Ceased
- 2019-05-31 JP JP2020567093A patent/JP7381500B2/ja active Active
- 2019-05-31 CN CN201980044404.1A patent/CN112424606B9/zh active Active
- 2019-05-31 US US16/973,028 patent/US12478693B2/en active Active
- 2019-05-31 CN CN202411990187.4A patent/CN119985995A/zh active Pending
- 2019-05-31 AU AU2019279001A patent/AU2019279001B2/en active Active
- 2019-05-31 EP EP19810892.0A patent/EP3803416A4/fr active Pending
- 2019-05-31 CA CA3100700A patent/CA3100700A1/fr active Pending
2023
- 2023-11-02 JP JP2023188467A patent/JP7583895B2/ja active Active
2024
- 2024-11-01 JP JP2024192794A patent/JP2025016675A/ja active Pending

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020036750A1 (en)	2000-09-23	2002-03-28	Eberl Heinrich A.	System and method for recording the retinal reflex image
JP2012503012A (ja)	2008-09-18	2012-02-02	セダーズ−シナイメディカルセンター	アルツハイマー病を検出するための光学的方法
US20120282169A1 (en)	2009-11-06	2012-11-08	Adlyfe, Inc.	Detection and treatment of traumatic brain injury
JP2013513619A (ja)	2009-12-10	2013-04-22	ザリージェンツオブザユニバーシティオブカリフォルニア	アミロイド結合剤
JP2013545516A (ja)	2010-10-25	2013-12-26	バードナー，スティーブン	アルツハイマー病、外傷性脳損傷、黄斑変性症、複数の神経変性障害および眼疾患の診断、進行および病気経過予想における網膜内のアミロイドの検出装置および方法
JP2017512834A (ja)	2014-03-19	2017-05-25	アミディス・ダイアグノスティックス・インコーポレイテッド	アミロイド標的剤及びその使用方法
WO2015188142A1 (fr)	2014-06-05	2015-12-10	Cedars-Sinai Medical Center	Diagnostic et surveillance d'une lésion cérébrale traumatique par imagerie des anomalies rétiniennes
WO2017004560A1 (fr)	2015-07-02	2017-01-05	The Regents Of The University Of California	Procédés et compositions pour des agrégats amyloïdes

Also Published As

Publication number	Publication date
US20210369873A1 (en)	2021-12-02
CN112424606B9 (zh)	2025-03-07
JP2025016675A (ja)	2025-02-04
EP3803416A4 (fr)	2022-05-18
MA52796A (fr)	2021-04-14
JP2021525875A (ja)	2021-09-27
AU2019279001B2 (en)	2025-11-27
JP2024028695A (ja)	2024-03-05
CA3100700A1 (fr)	2019-12-05
CN112424606A (zh)	2021-02-26
US12478693B2 (en)	2025-11-25
WO2019232422A1 (fr)	2019-12-05
CN112424606B (zh)	2025-01-14
EP3803416A1 (fr)	2021-04-14
JP7583895B2 (ja)	2024-11-14
CN119985995A (zh)	2025-05-13
AU2019279001A1 (en)	2020-12-03

Legal Events

Date	Code	Title	Description
2022-05-09	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220509
2022-05-09	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220509
2023-04-20	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230420
2023-04-25	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230425
2023-07-24	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230724
2023-08-31	TRDD	Decision of grant or rejection written
2023-09-04	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230904
2023-10-04	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231004
2023-11-07	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231102
2023-11-07	R150	Certificate of patent or registration of utility model	Ref document number: 7381500 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150

Publication	Publication Date	Title
JP7583895B2 (ja)	2024-11-14	外傷性脳損傷を検出するための組成物および方法
JP7664201B2 (ja)	2025-04-17	アミロイド標的剤及びその使用方法
JP7637288B2 (ja)	2025-02-27	神経障害を検出するためのリン酸化合物
JP2024177285A (ja)	2024-12-19	リン酸化タウタンパク質への結合を介した神経障害を検出する方法
CN117916225A (zh)	2024-04-19	N-杂环基取代的2-氰基-3-(萘-2-基)丙烯酰胺衍生物作为荧光团用于检测类淀粉蛋白和类淀粉样蛋白以诊断神经退行性病症
JP2013508384A (ja)	2013-03-07	アルファアドレナリン受容体モジュレーター
CN116327950A (zh)	2023-06-27	组合物用于治疗神经退行性疾病的神经精神症状的用途
US20260092037A1 (en)	2026-04-02	Crystalline salt forms of n-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl) methyl)-3-chloro-5-fluorobenzamide and methods of use thereof
CN121991127A (zh)	2026-05-08	用于对神经疾病进行检测的磷酸盐化合物